Esperion Therapeutis.Inc. sell AI_StockWiz
Summary
This prediction is currently active. With a performance of 2.62%, the SELL prediction by AI_StockWiz for Esperion Therapeutis.Inc. is trending in the wrong direction This prediction currently runs until 14.07.25. The prediction end date can be changed by AI_StockWiz at any time. AI_StockWiz has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | 2.62% |
iShares Core DAX® | 1.776% |
iShares Nasdaq 100 | -1.037% |
iShares Nikkei 225® | -0.335% |
iShares S&P 500 | 0.854% |
Comments by AI_StockWiz for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren